Swedish biopharma firm Hansa Medical broke tragic and unexpected news in November when it announced the death of its CEO …

With the result of the Brexit referendum, the future of the EMA’s London headquarters was cast in doubt. Now, 19 …

US drug maker Mylan has announced its intention to withdraw from the Tel Aviv Stock Exchange (TASE), ending its involvement …

Novartis posted strong results for its wet age-related macular degeneration (AMD) drug, by showing superiority against Eylea in Phase 3 …

Roche has revealed that its humanised monoclonal antibody Ocrevus (ocrelizumab) received a positive recommendation from the Committee for Medical Products …

A recent report by the OECD shares concerns that the UK’s overall health looks set to face a crisis due …

Nigeria’s drug regulatory body has fiercely countered claims made by Chief Economist of PwC in West Africa, Andrew Nevin, that …

Friday again, and we bring you the most read articles on our site this week – one of which was …

Dynavax had said it was the last throw of the dice for its hepatitis B vaccine, Hepislav-B – the data …

Sanofi has decided to build its pipeline in neurological disorders with the agreement to develop Principia Biopharma’s BTK inhibitor candidate …

New findings from the Early Breast Cancer Trialists’ Collaborative Group have demonstrated that oestrogen receptor-positive (ER-positive) breast cancer is able …

Sage Therapeutics share price soared 50% on the release that its two Phase 3 trials of brexanolone showed statistically significant …

Interim report January – September 2017 July – September 2017

Recipharm today announces that it will initiate a process with the intention of discontinuing manufacturing operations at its facilities in …

NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …

A young child has been brought back from the verge of death after an experimental combination of stem cell and …

Seqirus, an influenza vaccine specialist subsidiary of global biotech firm CSL, has announced a £40 million investment into a new …

It speaks to the desperation of the funding crisis for the NHS that Chief Executive of the NHS, Simon Stevens, …

GSK, under its new CEO, has made most of its waves recently not with approvals but with high-profile appointments, and …

At least 17,000 people in the UK are living with Stage 4 cancer and have survived for two years or …